Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:associated_with |
immunocompromised individuals
|
| gptkbp:avionics |
gptkb:LANA-1
v GPCR v IL-6 K8.1 |
| gptkbp:belongs_to |
Herpesviridae family
|
| gptkbp:catch_rate |
establishes lifelong infection
reactivates under immunosuppression |
| gptkbp:caused_by |
gptkb:multicentric_Castleman_disease
gptkb:primary_effusion_lymphoma gptkb:healthcare_organization |
| gptkbp:clinical_trial |
asymptomatic infection
symptomatic infection |
| gptkbp:discovered_by |
gptkb:1994
|
| gptkbp:distribution |
worldwide
|
| gptkbp:family |
gptkb:Herpesviridae
|
| gptkbp:genetic_diversity |
high genetic variability
multiple strains identified |
| gptkbp:genus |
gptkb:Rhadinovirus
|
| gptkbp:healthcare |
associated with cancer risk
requires monitoring in at-risk populations associated with increased cancer risk important in HIV co-infection management linked to transplant-related complications |
| gptkbp:hosts |
gptkb:Person
|
| https://www.w3.org/2000/01/rdf-schema#label |
Human herpesvirus 8
|
| gptkbp:is_known_for |
gptkb:HHV-8
Kaposi's sarcoma-associated herpesvirus (KSHV) |
| gptkbp:is_popular_in |
higher in certain geographic regions
|
| gptkbp:is_protected_by |
safe sex practices
|
| gptkbp:is_recognized_by |
AIDS patients
|
| gptkbp:is_vulnerable_to |
no approved vaccine
|
| gptkbp:nutritional_value |
encodes several oncogenic proteins
expresses glycoproteins for entry into cells produces viral interleukin-6 (v IL-6) expresses latency-associated nuclear antigen (LANA) |
| gptkbp:performance |
establishes latency in B cells
can reactivate in immunocompromised hosts |
| gptkbp:receives_funding_from |
funded by non-profit organizations
grants available for virology studies receives funding for cancer research supported by public health initiatives |
| gptkbp:replaced_by |
a patient with Kaposi's sarcoma
|
| gptkbp:research_areas |
vaccine development
therapeutic targets viral pathogenesis |
| gptkbp:research_focus |
immune response
cancer biology viral pathogenesis viral latency oncogenic potential |
| gptkbp:seed_dispersal |
double-stranded DNA
|
| gptkbp:social_responsibility |
gptkb:multicentric_Castleman_disease
gptkb:primary_effusion_lymphoma gptkb:HIV/_AIDS serological tests PCR testing cancers associated with HIV infection endemic in sub-Saharan Africa more common in certain geographic regions common in Mediterranean countries higher prevalence in immunocompromised individuals rare in Asia rare in North America |
| gptkbp:symptoms |
weight loss
fever night sweats lymphadenopathy lesions |
| gptkbp:transmission |
organ transplantation
saliva sexual contact blood transfusion |
| gptkbp:treatment |
gptkb:vaccine
radiation therapy chemotherapy drug resistance antiviral therapy studying combination therapies late diagnosis improved with early intervention variable prognosis based on disease stage need for effective therapies in immunocompromised patients difficulties in vaccine development exploring immune modulation investigating novel therapies resistance to antiviral drugs |
| gptkbp:bfsParent |
gptkb:endemic_Kaposi's_sarcoma
|
| gptkbp:bfsLayer |
4
|